De La Medicalizacion A La Farmaceuticalizacion

From Medicalisation to Pharmaceuticalisation - A
Sociological Overview. New Scenarios for the Sociology

of Health
Mara Tognetti Bordogna ¹ ∗
¹ University Milano-Bicocca, Department of Sociology and Social Research, 8 Via Bicocca degli Arcimboldi, Edificio
U7, 20126 Milano, Italy
KEYWORDS ABSTRACT
The aim of this paper is to analyse the sociological

literature on pharmaceuticalisation and see how sociology
helps us understand and explain the phenomenon. We
then discuss how sociology, especially in Anglo-Saxon
countries, defines the process of pharmaceuticalisation
Medicalisation and how this last is evolving. The paper points out that,
Pharmaceuticalisation while medicalisation remains a key concept for health
Drugs sociology, it is increasingly being queried and/or
Health extended to allow for a techno-scientific era of
Sociology of health biomedicalisation (Clarke et al. 2003) and to acknowledge
Disease the importance of the pharmaceutical industry in this
process (Williams, Martin and Gabe 2011a, 2011b).
Particular attention will be paid to the process of
pharmaceuticalisation as brought about not just by
doctors and their prescriptions, but by the central role of
pharmaceutical promoters and the marketing of drugs.
Foreword
Medicaments are complementary to medicine: they support and justify one

another. A drug prescribed is a symbolic or real part of the cure. Drugs
symbolise the fact that a disease can be treated, the patient is curable. That
makes the disease something mentionable, for if there is a drug for a
complaint, it becomes ‘normal’. The symbolic and the real value of
∗
Contact address: mara.tognetti@unimib.it (M. Tognetti Bordogna)
Social Change Review ▪ Winter 2014 ▪ Vol. 12(2): 119-140

DOI: 10.1515/scr-2015-0002
M. Tognetti Bordogna – From Medicalisation to Pharmaceuticalisation...
medication: with the development of multinational pharmaceutical

companies, biomedicine, the internet and new epidemics, the terms have
undergone a shift of meaning (Terraneo, Sarti and Tognetti Bordogna 2014;
Sironi and Tognetti Bordogna 2009). An ever more imposing array of drugs
are being prescribed by doctors to contain and control all new forms of
pathology and social problems (Zola 1972; Illich 1976), giving rise to a
process now known as the medicalisation of society (Conrad, Gabe and
Williams 1992).
In addition to the above factors, we are now witnessing the rise of
citizen expertise about the diseases of society, and the resort to drugs in
order to enhance social performance, relating, and the response to challenge,
rather than in response to illness as such. This process has been dubbed the
pharmaceuticalisation of society (Williams, Gabe and Davis 2008). It consists
in the use of drugs or medication to improve individual performance,
without consulting a doctor.
While the medicalisation process has now taken theoretical root in the
sociology of health, there is much less familiarity with the attendant
concepts of biomedicalisation and pharmaceuticalisation. In this paper we
shall be discussing pharmaceuticalisation and how sociology may help
understand and explain the phenomenon. We shall be looking at Anglo-
Saxon sociology in particular, for its description of the pharmaceuticalisation
process and how it is spreading.
From medicalisation to pharmaceuticalisation
Conrad was one of the first scholars to define the concept of medicalisation
(Conrad 1992; Conrad and Schneider 1992) and describe its impact (Conrad
2007). He sees it as a process by which problems lying outside medicine
begin to be treated and defined as medical. He points out that over the last
thirty years there has been an increase in ‘living issues’ being turned into
disorders, syndromes connected with behaviour, psychic states or physical
conditions. The author wonders whether this is a new epidemic or a new
120
ability on the part of medicine to deal with pre-existing issues. Or do we

now find medicine diagnosing a range of issues as problems subject to
medical treatment, even though there is little clear evidence that they are
medical in nature (Conrad 2007). In the name of clarifying the process of
medicalisation, Conrad and other authors (Rodeschini 2012) have mounted
studies to explore the social basis for this expanding jurisdiction of medicine
which forms one of the most powerful late-twentieth-century
transformations in the West (Clarke et al. 2003). The 1980s marked the
turning point in the medicalisation process, with not only physicians
occupying centre-stage in the analysis, but patients, the pharmaceutical
industry, the media and the State.
To Conrad (2007, 2009), along with biotechnology and managed care,
one of the main factors changing the key mechanisms of medicalisation has
been the transformation of patients into consumers. Conrad (2007) also
points out the leading part played by technology in the medical process,
spurred by the pharmaceutical industry and the manufacturers of
biotechnology.
Certain authors in the nineties talked of a process of de-medicalisation.
Moynihan and Smith (2002) saw the new information and communication
technology as a potent tool for de-medicalisation, since it tends to make the
patient more responsible. With the capillary spread of information, people
have become more aware of the cost-benefit of medicalising their lives.
Others (Ballard and Elston 2005) argue that medicalisation is becoming more
and more two-way and multi-dimensional. To listen to Conrad and
Schneider (1992), medicalisation is part and parcel of modernity. Elston et al.
(2002) wonder whether we are witnessing a historical turning-point towards
a post-modern era; that more medicalisation may well be in store.
We note the beginning of a trend among scholars, to whom
medicalisation is no longer a sufficient interpretive category to account for
the ever more complex medical and social phenomena. Though
medicalisation has remained a key concept in the sociology of health,
increasingly we see it being challenged, its boundaries stretched to cover a
121
techno-scientific era of biomedicalisation (Clarke et al. 2003), while there is

increasing recognition of the part being played by the pharmaceutical
industry in this process (Williams, Martin and Gabe 2011a, 2011b).
The much-debated change in progress within medicine is well
illustrated by the works of Clarke et al. (2003, 2009). Clarke focuses on
technology spurring medicalisation; she points out the limitations of
classical medicalisation theory and suggests it should be broadened into
‘biomedicalisation’. Clarke and Shim (2009) argue that medicalisation no
longer explains the full picture emerging from their research and claim that
biomedicalisation, taking its cue from medicalisation, shifts the emphasis
onto the scope for techno-scientific intervention, (re)organization and
transformation.
Picking up from Latour, the two authors suggest that the term ‘techno-
science’ covers the need to see technology and science as ‘co-constitutive’
(Clarke et al. 2009); they deny the existence of ‘pure forms’ of scientific
research or technology divorced from practical application.
‘Techno-science’ lends itself, again, to new kinds of intervention, in
sickness and in health, in treatment and in the organization of medical
therapy, as well as in the way we frame and lead our lives. If medicalisation
(Conrad 2007) is about controlling and normalizing human functioning,
biomedicalisation (Coveney, Gabe and Williams 2012) focuses on changes in
medicine and on the human body: not just to cure, but to personalize,
enhance and optimize health. Biomedicine and its tools are of use not just to
pathology, but in ensuring better health in future (Clarke et al. 2009).
Today this theoretical framework (medicalisation and
biomedicalisation) is itself being questioned by some scholars. Is it sufficient
to explain the massive and increasing development and use of drugs, and
the ever more powerful role of the pharmaceutical industry, not just in
producing and selling, but also in validating their wares (Metzl and Herzig
2007).
Various authors (Abraham 2009, 2010; Bell and Figert 2012) have
pointed out that social scientists have long studied drugs and the drug
122
industry, but in relation to increasing consumption of the product (Busfield

2006), or in relation to the role drugs have in medicalising society (Williams
et al. 2008a). Such authors have seen the crucial step to be recognition of the
growing importance of the pharmaceutical industry in medicalisation
(Williams et al. 2008). In Conrad’s view (2007), although doctors are still
watchdogs as to the use of many drugs, the role of the pharmaceutical
promoters is on the increase, aggressively targeting the public and not just
doctors. While recognising that medicalisation swells the amount of
medication used, Abraham (2010) points out that the theoreticians of
medicalisation have concentrated on the interaction between the medical
professions, patients and public health organizations, but have paid little
attention to drugs and the drug industry.
Only in the last ten years, however, have we seen the rise of specific
analysis of the political, economic and medical processes leading to use of
the term ‘pharmaceuticalisation’. The term was first used in anthropology by
Mark Nichter (1989) and later in sociology by Williams and his team
(Williams, Gabe and Davis 2008). As Bell and Figert have written (2012), the
concept of pharmaceuticalisation has largely been developed, in recent
years, by Anglo-Saxon scholars who have highlighted various potential
aspects of the phenomenon.
Pharmaceuticalisation of life and society
The process of pharmaceuticalisation is found in milieus that are

traditionally not part of the medical domain (Abraham 2010b); it includes the
biological effect of chemical substances on the human body, a consumer
craze to use technology as a solution to life’s problems, and the
pharmaceutical industry’s interest in augmenting consumption of
medicaments (Fox and Ward 2009). Such scholars believe ‘we are witnessing
the pharmaceuticalisation of domestic life’ along with the domestication of
pharmaceutical consumption (Fox and Ward 2009). To Williams and Martin
(2009), pharmaceuticalisation means the transforming of human skills and
123
conditions into pharmaceutical questions of treatment or enhancement.

Abraham (2010b) sees it as a process by which social, behavioural or physical
conditions are treated or construed by doctors and patients as needing
medical drug treatment.
Around these definitions the argument between the medicalisation
and the pharmaceuticalisation factions has focused on whether the latter
concept is a necessary one or could simply be included under the heading of
medicalisation. The debate as it has so far developed may be summed up
under three main positions (Busfield 2006; Abraham 2010; Williams, Martin
and Gabe 2011a, 2011b). More recently various authors have divided over
the relevance of their positions to the complexity of society and to the global
situation (Bell and Figert 2012; Williams, Gabe and Martin 2012).
It is Busfield’s contention (2006; 2010) that, to understand
pharmaceuticalisation, one must focus on the main actors behind the
expansion of this process: the pharmaceutical firms, doctors, the public,
governments and insurance companies. The pharmaceutical industry calls
the tune with the scientists engaged in developing and experimenting with
drugs; its strategy is deliberately to generate demand, turn pathology into a
market commodity and create new markets for its wares. The doctoring
fraternity develops ‘new medication’, often in league with the
pharmaceutical industry, and controls access to the drugs by making them
subject to prescription. In its turn, the public in consumer societies use
information and communication technology, giving rise to the figure of the
‘expert patient’ (Busfield 2010). Lastly, governments and insurance
companies establish a framework for health care. Busfield thus sees
pharmacology as reiterating the global pattern of wealth/poverty,
power/inequality. From a commercial standpoint, he argues, the ideal
product is one that achieves a patent, is used by a broad spectrum of persons
over a long period, and can be sold at a price significantly higher than the
cost of producing it. Standard patents last twenty years, he points out, but
may in some circumstances be prolonged. For instance, Prozac has been
dressed up as Sarafem and is prescribed for Premenstrual Dysphoria
124
Disorder. As patents come to an end and brand drugs are replaced by

generic drugs, Busfield adds, the growth rates fall worldwide, except for
China, Brazil and India.
Abraham (2010b) emphasises that the concept of pharmaceuticalisation
is an important one and presents a complex profile. While acknowledging
that the term somewhat overlaps with medicalisation, he points out
significant differences between the two phenomena. Whereas expansion of
drug use affects pharmaceuticalisation per se, the exponents of
medicalisation are only interested in how that expansion reflects an increase
in the areas of life that used to lie outside medical jurisdiction and are now
being presented as medical issues. Abraham echoes Conrad (2007) in
claiming that when the US Food and Drug Administration (FDA) changed
its rules on direct advertising of drugs and the customer’s requirement of a
prescription, that made it easier for medicaments that should be prescribed
by a doctor to be promoted outside the medical conditions approved by the
lawgivers. The change seems to have induced pharmaceutical companies to
‘plug’ pathologies such as ‘generalized anxiety disorders’, thereby
increasing medicalisation. But, as he argues, the concept of medicalisation is
inadequate to explain Conrad’s point; he takes the particular example of
Ritalin sales. Ritalin has been available since the 1960s, but has increased its
sales in the last decade. That might partly be set down to prescription
patterns, but it is also due to the fact that medication is now being favoured
over psychotherapy in such disorders. The same goes for obesity, which is
now increasingly being treated by medication and less by diet or surgery.
This all goes to show that pharmaceuticalisation may increase without a rise
in medicalisation since, Abraham argues, certain drugs are more and more
being used to treat consolidated medical conditions without entailing the
transformation of a non-medical into a medical issue. He concludes that
pharmaceuticalisation may occur without medicalisation.
This leads Abraham to claim that we need the term
pharmaceuticalisation more and more, since medicalisation does not do full
justice to the empirical phenomena it purports to describe. Again,
125
pharmaceuticalisation may not have increased in all fields of medicine: it is

precisely by studying areas of contraction that we can grasp the nature and
extent of the phenomenon. He goes on to point out that, as a sociological
concept, pharmaceuticalisation must be something more than the simple
observation that drugs are increasingly present in society. The factors that he
sees as explaining pharmaceuticalisation are biomedicalism (including
research, development and innovation by the pharmaceutical industry, and
especially the increasing ability of biomedical science to find new
pharmaceutical solutions to new or already known diseases), marketing of
drugs by the pharmaceutical industry, consumerism, and public policy
regulating the sector. Such factors need examining in relation both to the
growth and to the contraction of pharmaceuticalisation.
On the question of biomedicalism and its role in the process of
pharmaceuticalisation, Abraham points to the steady growth (doubling and
tripling in some instances) of some prescription medicaments in the USA,
Canada and Australia. In the case of Viagra, sales nearly doubled in the four
years following introduction (1998), while Ritalin sales rose five times in the
corresponding ten years (1992). The biomedicalist view has taken firm root
in industry, techno-science and public opinion, and this makes it possible for
anyone suffering from hitherto undiagnosed and untreated conditions like
ADHD1, depression or erectile dysfunction to obtain the medication they
need. Abraham is not convinced of biomedicalisation tout court in the
process of pharmaceuticalisation: not only is it technically improbable, but if
we broaden the diagnostic criteria, that may bring about both medicalisation
and the discovery of sufferers who were previously undetected. Another
weakness of the biomedicalist argument is that pharmaceuticalisation is
spurred not so much by scientific discoveries responding to new medical
needs, but by an increase in promotion and marketing.
Marketing is a side to the pharmaceutical sector that has grown
greatly. Medical experts have been brought into marketing strategy and
involved in developing products. Pharmaceutical companies fund meetings
1 Attention Deficit Hyperactivity Disorder (ADHD).
126
and symposia, and also magazines and magazine articles that speak well of
certain drugs. They hire public relations consultants to get the mass media to
hype a product, or to block or hold back certain news items.
The key feature of the consumer market is the knowledgeableness of
consumers and consumer associations. Abraham (2010) sees this as not
necessarily boosting pharmaceuticalisation: it may breed antagonism or
collaboration, or both. Drug consumers have been seen (Bell and Figert 2012)
as either injury-oriented adversaries or access-oriented collaborators. The
former believe they have been harmed by a drug and mount campaigns in
the media and the law courts against the manufacturers - a practice that is
now widespread in the USA. Antagonism by consumers does not increase
pharmaceuticalisation, and may reduce it by sowing doubt as to a drug’s
safety. Consumer collaborators, on the other hand, believe that medicaments
should be available to a wider number of patients. Their behaviour tends to
pharmaceuticalisation, since pressure groups in favour of faster access to a
drug will work on government agencies to speed up approval of the new
product. Abraham argues that if active consumer groups are backed by
pharmaceutical companies, the process of pharmaceuticalisation they
stimulate will outweigh the de-pharmaceuticalisation by consumer
adversaries.
A further boost to pharmaceuticalisation is given by de-regulation
policies and especially by national bodies allowing the drug markets to
expand.
To Abraham the main driving force comes from industrial marketing
which causes pharmaceuticalisation to outstrip medicalisation. It also
surpasses the biomedical booster mechanism, which he sees as a weak
explanation. Marketing efforts have far exceeded research and development,
while the pharmaceuticalisation of low-yield/high health-need therapy
areas has remained constant or diminished. The weakness of biomedicalism
as an explanation for growing pharmaceuticalisation, and the relative
increase in cases of drug-related damage are of more than academic interest.
They show that augmented pharmaceuticalisation is not fuelled mainly by
127
an increased pharmaceutical ability to meet and foresee health needs. It is

rather the sociological factors of consumerism, state de-regulation policies,
the commercial priorities of industry, the promotion of products and
medicalisation that have expanded pharmaceuticalisation way beyond any
such ability (Abraham 2010).
Williams, Martin and Gabe (2011b) take a quite different line. Starting
out from medical sociology studies, they propose a broader conceptual
framework for pharmaceuticalisation than Busfield and Abraham adopt.
Williams’ theories take their cue from science and technology studies (STS)
as well as health sociology. Adopting a post-modern approach, he defines
pharmaceuticalisation as a dynamic, complex, heterogeneous socio-technical
process forming part of what we might call a pharmaceutical regime. This
may be seen as the network of institutions, organizations, actors and
artefacts, as well as the cognitive structures associated with creating,
producing and using new therapeutic products. This regime has been built
around the development of pharmaceutical products ever since they were
introduced in the nineteenth century, and centres on the chemical
technology represented by the pill. One of the basic dynamics of this regime
is its ‘continuous commercial, clinical and geographic expansion’ (Williams,
Martin and Gabe 2011b). This all ties up with a macro level (developing,
experimenting with and regulating drugs) and a micro level (use of drugs in
medical practice and daily life). Williams and team see
pharmaceuticalisation as a multi-dimensional, multi-level concept and do
not rule out de-pharmaceuticalisation, or indeed forms of social resistance to
pharmaceuticalisation. They see it as a complex, dynamic process building
up a long-term pharmaceuticalisation regime. This is still in progress and
includes various distinct socio-economic activities and actors, such as:
doctors, patients, consumers and regulators. The degree and extent of
pharmaceuticalisation may vary from case to case and depends on the
context and on interaction among various groups of actors (Williams, Martin
and Gabe 2011b).
Williams thinks pharmaceuticalisation is not only on the increase but
128
is a full-blown scientific and social concept. At least six social dimensions

(Williams, Martin and Gabe 2011a) need to be studied in analysing the
trends and transformations by which society is pharmaceuticalised: (1)
redefining and reconfiguring health problems as amenable to
pharmaceutical solution, (2) forms of governance in constant change:
globalization and the new role of regulatory agencies in promoting
innovation, (3) health problems being re-framed by the media and in
popular culture as solvable by pharmaceutical means, (4) creating new
techno-social identities and mobilising patients and consumer groups with
regard to drugs, (5) use of non-medical medicaments and creating new
consumer markets, (6) pharmaceutical innovation.
At the root of pharmaceuticalisation, the argument runs, there is a
steady increase in the sales and production of medicaments in all countries,
the chronicising of health problems, and medicalisation of everyday life.
This last position is shared with Conrad (2007) who maintains that
pharmaceutical firms sell disease as well as medication. Disease has become
commodifiable, as defined by Moynihan and Smith (2002): the social sense
of disease is being replaced by the commercial sense of it, including the
turning of minor daily problems into medical problems, considering risks as
a disease, hiking estimates in order to maximise markets, and lastly aiming
publicity at the end-user.
The second set of factors stems from the changing relations between
regulatory agencies and the pharmaceutical industry following measures
such as reforms reducing the legal obstacles or making regulatory agencies
more dependent on the pharmaceutical industry; new policies increasing the
role of regulatory agencies in pharmaceutical promotion and innovation,
globalization of consolidated models of governance based on
pharmaceutical industry interests (Williams, Martin and Gabe 2011a),
especially in the developed world. A number of sociology studies (Abraham
1995, 2009, 2010a, 2010b) on anti-inflammatory drugs, anti-depressants and
sleeping tablets show that pharmaceutical firms in some cases have a
privileged channel to the regulatory agencies. Other studies have dealt with
129
the role of regulators vis-à-vis the patient demand to speed up approval of

new drugs (Daemmrich 2004). Others again show that regulation of drugs
does not always manage to benefit public health. The close link between
state offices and pharmaceutical companies (Williams Martin and Gabe
2011a) has led to schemes to reduce the time of reviewing newly patented
medicaments, and to ultra-fast approval of drugs for ‘serious’ diseases or for
‘life-threatening conditions’ on the basis of fewer data than would properly
suffice to demonstrate a product’s safety and efficacy. By this last practice
some 14% more drugs have been approved in the last fifteen years (Garattini
and Bertele 2001). Williams and his team argue that, in following these
measures, regulatory agencies have gone from being guardians of public
health, to holders of the key to promoting innovation. There is meanwhile
globalization of the Western regulatory system by the creation of bodies
such as the International Conference on Harmonisation which pools
regulators from Europe, Japan and America. The globalization process is
also boosted by new markets opening in emerging economies, and by
contracting out drug development to developing countries where
experimentation costs are lower than in the West.
On the third point, a large part is played by the media featuring old
and new syndromes on programmes and news coverage (for example,
restless leg syndrome). Their role as ‘presenters and amplifiers’ of issues,
along with forms of occult advertising, helps to boost pharmaceuticalisation.
According to Martin (2006), one should not underestimate pill or capsule
design, either: it tunes in to the potential consumer’s wavelength via
television or the printed word. The new media and the Internet are likewise
coming to play an increasing role in the pharmaceuticalisation process, as
sources of information about specific products, and also as channels of direct
purchase. Fox and Ward (2009) think the consumption of medicaments is
being domesticated by computer-mediated access, and that everyday life is
itself being pharmaceuticalised in that pills are now seen as ‘magic bullets’
against a range of daily problems. Williams and team (2011a) say that the
Internet may cut two ways in the process of medicalising and
130
pharmaceuticalising society: it may open up new channels of

pharmaceuticalisation, but also give rise to forums of resistance.
The fourth point about new social identities concerns
patients/consumers’ growing expertise about their own health. They are
now informed actors assessing risks and benefits, taking informed decisions
about their own treatment since the relevant information is ‘out there’ on
line, at the click of a mouse. Internet users may also form into communities,
self-help groups (Rossi and Tognetti Bordogna 2013). All of this has
implications for the individual’s sense of self (Rose 2007), as well as the role
of individuals in the public domain. Here again, there is scope for
pharmaceuticalisation being boosted without doctor mediation, but also for
resistance to the phenomenon. As we have said à propos of Abraham (2009),
the real effectiveness of patient activism or collective consumer mobilisation
depends whether they are supporting or opposing the pharmaceutical
industry’s basic interests. The latter has also been known to capture patients’
and consumers’ allegiance (Jones 2009) by informing and educating them.
The words of expert patients have proved especially useful in
pharmaceutical campaigns. Clearly the process of patient-induced
pharmaceuticalisation is likely to be the greater when the treatment being
sought is urgently needed.
Another form of pharmaceuticalisation of everyday life is the use of
drugs for non-medical purposes (fifth factor): the enhancement of health in
the healthy. Here people are driven by a desire for self-improvement,
improving their own performance. Such behaviour is classed as
enhancement, though the literature divides on this (Elliot 2003). Conrad
(2007) thinks we should distinguish three types of enhancement bound up
with normalisation, in which biomedical enhancement is used by doctors
and patients to bring the body up to society’s standards of normality; repair,
where biomedical treatment is used to adjust and/or rejuvenate the body to
its previous shape; and lastly, the desire to boost individual performance to
ensure competitive advantage. Once again we find medicalisation and
131
pharmaceuticalisation together; in the second case, there is no involvement

of doctors in the phenomenon.
There has been keen interest in the promise of new drugs to enhance
cognitive performance. But if medicines are presented as boosters (Williams,
Martin and Gabe 2011a), that may create new markets for drugs sold straight
to the consumer without medical control.
Lastly, the sixth factor, pharmaceutical innovation and the creation of
new future health scenarios. This includes areas that fall under the sociology
of innovation and especially the phenomena of invention and creation:
setting up an expectation that some future possibility may be fulfilled. In
other words, patients are induced to invest indirectly and collectively in
future pharmaceutical discoveries to treat the complaints they are suffering
from (Novas 2006). This involves the field of genetic- and genomic-medicine
that Williams uses as an example, entailing great speculation as to a new era
of personalized or tailor-made medicine, targeting the individual genetic
profile. In this case one imagines a considerable reduction of hostility to
drugs – a traditionally common feature: they here hold out the hope of
greater effectiveness in being tailored to specific genotypes. Pharmaceutical
innovation of this kind bears on policy decisions and on a future vision of
health. Williams thinks that such pharmaceuticalisation of the future may
help keep the ball in the biomedical court, creating investment and
innovation in the quest for new medicines as the best way of improving
human health. But how new pharmaceutical technology translates into
practice is a far more complex matter. Pharmacological data of the kind
described above are finding their way into all stages of research and
development. For the time being, progress is slow and patchy, with little
evidence of enormous benefit of the kind expected (Williams, Martin and
Gabe 2011a, 2011b). Study and research on this scale conjures up thoughts of
market segmentation, the proliferation of genetic experimentation, even
racial policies. Despite the investment in research and the broadening of the
canvas with drugs deriving from genomics, Williams and colleagues feel
that pharmaceutical innovation is marking time. Confidence in the
132
revolution of biotechnology remains high, all the same, a fact that

sociologists of expectation should view with a critical eye. For the sociology
of expectation, as they well know, teaches that we must examine our own
expectations as partners in the field in question, including the various future
pharmaceutical scenarios we claim to be analysing (Williams, Martin and
Gabe 2011a, 2011b).
The six sides to pharmaceuticalisation listed by Williams et al. have
certain features in common, such as: expansion of the drug market beyond
traditional areas, both geographical (the developing world) and applicatory
(healthy persons); the growing scope for regulation; the constant bid to get
round medical control and set up direct contact with patients/consumers;
and lastly, colonization of the world of life. These are all specific features of
pharmaceuticalisation, enabling us, incidentally, to distinguish it from
medicalisation. What emerges is the central role of the pharmaceutical
industry, eluding medical control and reframing the role of the patient
and/or consumer. It also follows that pharmaceuticalisation has increasing
analytical value as a sociological concept; likewise that it is important to
study what the pharmaceutical industry is getting up to, it being the prime
actor in contemporary biomedicine. Pharmaceuticalisation may claim to be a
new frame of interpretation for the sociology of health, and one likely to
yield new prospects.
Williams concludes his work by suggesting that, amid the welter of
approaches adopted to date – political-economic and realist, elements of
social constructionism, STS studies, Foucault and Habermas approaches -,
we should leave the door open for the time being on our various
interpretations of and theories about pharmaceuticalisation, since it is still
premature, if not useless, at this stage to single out any specific yardsticks of
interpretation. Many important prospects of research are in the pipeline, for
example: the role of industry in expanding pharmaceutical markets to
include new non-medical conditions or complaints; the changing role of
regulatory agencies; new thoughts on the role of patients and consumers in
the development and use of drugs. Or again: how the world of life, everyday
133
life and the future of health are coping with colonization by pharmaceutical
firms and their ‘solutions’. Last but not least, what role sociologists may
have as co-producers of issues regarding the pharmaceuticalisation of
society. The conceptual framework, then, is well delineated, but it leaves
great scope for in-depth studies and research.
In spring-summer 2012 Social Science and Medicine carried an
interesting exchange of views between Bell and Figert (2012) and Williams,
Gabe and Martin (2012). In reviewing the debate on medicalisation and
pharmaceuticalisation, Bell and Figer argued that since we live in a post-
modern society, we need a post-modern theory (or set of analysis tools)
enabling us to explain hybrids: we can no longer pretend there is any radical
difference between the human and the material world. Yet modern theories
are unable to explain hybrids, or the collapse of basic boundaries between
humans and animals, organisms and machines, physical and non-physical
entities. In the second place, it is less and less likely that nation-States will
mediate where economic, political and social processes are concerned; hence
we need to look ‘above’ the State towards extra-state rules and ‘below’ the
State at the movements of people, technology and ideas, if we wish to
understand how processes such as pharmaceuticalisation work (Bell and
Figer 2012). This gives central importance to the issue of globalization and
choice of country, as well as pharmaceutical companies and
patients/consumers. Referring to the work of anthropologists, Bell and Figer
(2012) complain that sociologists are still too Western-biased in studying the
issue of pharmaceuticalisation. It was anthropologists in fact (Petryna 2006),
who introduced the notion of ‘pharmaceuticalising public health’ into the
case study on drugs that connect global dynamics among states, NGOs and
pharmaceutical companies with local communities. They cite the example of
the Brazilian policy (Biehl 2008) for preventing and treating AIDS by free
distribution of ARV to all registered cases of AIDS. This policy has reduced
AIDS mortality and the demand on hospital services, as well as improving
the lives of HIV/AIDS sufferers. By designating AIDS as a ‘national disease’,
Brazil has set up a ‘captive market’ for the pharmaceutical industry, not just
134
for already available drugs, but also for the future, seeing that new drugs are
being developed to replace ‘old treatment protocols’ when these lose
effectiveness (Biehl 2008). Another instance that they cite of
pharmaceuticalising public health is the treatment of asthma sufferers in
Barbados (Whitmarsh 2008).
Williams, Gabe and Martin (2012) came back in critical vein. Studies by
sociologists on pharmaceutical firms and products date back to the mid-
1980s, before the term pharmaceuticalisation was coined. They
acknowledged the contribution of anthropologists, but warned that one
should not assume that all anthropological research into the world’s South
was part of a post-modern turning-point. They (Williams and colleagues)
maintained there are many other factors to consider in the process of
pharmaceuticalisation, such as resistance by consumers/patients, de-
pharmaceuticalisation, the challenge posed by restructuring pharmaceutical
industries, outsourcing to developing countries and conducting trials there.
They ended by calling for a framework within which to cover the full
complexity and global aspects of the problem. This especially meant paying
attention to resistance and ambivalence, the constant role of the doctor-drug
link, the crisis of innovation in industry and the contribution of research
both in the North and in the South.
Conclusions
We have discussed the need to move beyond and extend the notion of
medicalisation and embrace that of pharmaceuticalisation which better fits
the new phenomena of consumption, production and marketing of drugs.
We are witnessing a new theoretical and analytical dimension, and
pharmaceuticalisation still has points of definition and theory that need
clarifying and consolidating, however much Williams may regard it as a
fully-formed social and scientific concept (Williams et al. 2012). The
phenomenon proves to hinge on the role of drug production and marketing.
135
We went on to show how in the Anglo-Saxon debate the notions of

medicalisation and pharmaceuticalisation are not always mutually
exclusive, but frequently highlight different features. In analysing the debate
in progress, we find that our present society contains at one and the same
time phenomena of pharmaceuticalisation and of de-pharmaceuticalisation,
as well as pharmaceuticalisation of public life.
We have taken our cue from the arguments of the main theoreticians
of this subject, and gone on to analyse from differing perspectives the
various sociological dimensions upon which the concept of
pharmaceuticalisation rests.
Lastly, our article has shown how the phenomenon of
pharmaceuticalisation is important to understand the pattern of medicament
consumption in our society, and also the roles of the various actors in the
health, wellness and illness settings, not forgetting individuals’ concern with
their own performance. This enables the analysis to cover the role of actors
on the micro plane (the individual), the middle plane (the relation between
individuals and their doctor, the degree of performance society expects of
them, and the pharmaceutical companies) and the macro plane
(globalization of our drug-conscious society and public health policies of de-
regulation or pharmaceuticalisation).
Limits and future prospects
This paper does not claim to be exhaustive or generalizable: it is mainly a

survey of the literature and the debate over theory, and is hence not backed
up by systematic research findings. It also focuses largely on the Anglo-
Saxon literature. While aware of these limitations, we feel it may nonetheless
provide a useful summary of the debate and a starting point for
investigation of the phenomenon, whether in Anglo-Saxon countries or the
rest of the world, and especially in the BRICS countries. In future we believe
that studying the process of pharmaceuticalisation and de-
pharmaceuticalisation will assume increasing importance in the sociology of
health. Via such studies we will be able to analyse the various new forms of
136
aggregation and participation by individuals, and the different forms of

aggregation linked to health and disease.
References
Abraham, John. 1995. Science, Politics and the Pharmaceutical Industry. London:
Routledge.
Abraham, John. 2008. “Sociology of pharmaceuticals development and
regulation: a realist empirical research programme.” Sociology of
Health & Illness 30(6): 869-885.
Abraham, John. 2009. “The pharmaceutical industry, the state and the NHS.”
In The New Sociology of the Health Service, edited by Jonathan Gabe
and Michael Calnan, 99-120. London: Routledge.
Abraham, John. 2010a. “The Sociological Concomitants of the
Pharmaceutical Industry and Medications.” In Handbook of Medical
Sociology, edited by Chloe Bird, Peter Conrad, Allen Fremont and
Stefan Timmermans, 290-308. Nashville: Vanderbilt University Press.
Abraham, John. 2010b. “Pharmaceuticalization of Society in Context:
theoretical, empirical, and health dimensions.” Sociology 44(4): 603-
622.
Ballard, Karen and Mary Ann Elston. 2005. “Medicalisation: A Multi-
dimensional Concept.” Social Theory and Health 3(3): 228-241.
Bell, Susan and Anne E. Figert. 2012. “Medicalization and
Pharmaceuticalization at the Intersections: Looking Backward,
Sideways and Forward.” Social Science & Medicine 75(5): 775-783.
Biehl, João. 2008. “Drugs for all: the Future of Global AIDS Treatment.”
Medical Anthropology 27(2): 99-105.
Busfield, Joan. 2006. “Pills, Power, People: Sociological Understandings of
the Pharmaceutical Industry.” Sociology 40(2): 297-314.
Busfield, Joan. 2010. “‘A Pill for Every Ill’: Explaining the Expansion in
Medicine Use.” Social Science & Medicine 70(6): 934-941.
Clark, David. 2002. “Between hope and acceptance: the medicalisation of
dying.” British Medical Journal 324: 905-907.
Clarke, Adele, Janet K. Shim, Laura Mamo, Jennifer Ruth Fosket, and
Jennifer R. Fishman. 2003. “Biomedicalization: Technoscientific
Transformations of Health, Illness, and U.S. Biomedicine.” American
Sociological Review 68(2): 161-194.
Clarke, Adele, Laura Mamo, Jennifer Ruth Fosket, Jennifer R. Fishman, and
Janet K. Shim. 2009. Biomedicalization: Technoscience and
137
Transformations of Health and Illness in the U.S. Durham: Duke

University Press.
Clarke, Adele and Janet Shim. 2009. “Medicalizzazione e
biomedicalizzazione rivisitate: tecno-scienze e trasformazioni di
salute, malattia e biomedicine.” Salute e Società 2 (Fascicolo EN2): 223-
257.
Conrad, Peter. 1992. “Medicalisation and Social Control.” Annual Review of
Sociology 18: 209-232
Conrad, Peter. 2007. The Medicalization of Society: On the Transformation of
Human Conditions into Treatable Disorders. Baltimore: Johns Hopkins
University Press.
Conrad, Peter and Joseph W. Schneider. 1980. “Looking at Levels of
Medicalization: A Comment on Strong's Critique of the Thesis of
Medical Imperialism.” Social Science & Medicine. Part A: Medical
Psychology and Medical Sociology 14(1): 75-79.
Conrad, Peter and Joseph W. Schneider. 1992. Deviance and Medicalization:
from Badness to Sickness. Philadelphia: Temple University Press.
Coveney, Catherine, Jonathan Gabe, and Simon Williams. 2012.
“Potenziamento della capacità mentale? Dalla medicalizzazione della
cognizione alla farmacologizzazione delle routine mental life”. Salute
e Società 2 (Fascicolo suppl. 2): 145-159.
Daemmrich, Arthur. 2004. Pharmaco Politics. Chapel Hill: University of North
Carolina.
Elliot Carl. 2003. Better Than Well: American Medicine Meets the American
Dream. New York: W. W. Norton.
Elston, Mary Ann, Jonathan Gabe, David Denney, Raymond Lee, and Maria
O'Beirne. 2002. “Violence against Doctors: a Medical(ised) Problem?
The Case of National Health Service General Practitioners.” Sociology
of Health & Illness 24(5): 575-598.
Fox, Nick and Katie Ward. 2009. “Pharma in the Bedroom and the Kitchen.
The Pharmaceuticalisation of Daily Life.” Sociology of Health & Illness
30(6): 856- 868.
Garattini, Silvio and Vittorio Bertele. 2001. “Adjusting Europe’s Drug
Regulation to Public Health Needs.” The Lancet 358(9275): 64-67.
Illich, Ivan. 1976. Medical Nemesis. New York: Pantheon; Ital. trans. 2005.
Nemesi medica. L’espropriazione della salute. Milano: Boroli Editore.
Jones, Kathryn. 2009. “In Whose Interest? Relationships between Health
Consumer Groups and the Pharmaceutical Industry in the UK.” In
Pharmaceutical and Society: Critical Discourses and Debates, edited by
138
Simon J. Williams, Jonathan Gabe and Peter Davis, 112-125. Oxford:

Blackwell.
Martin, Paul. 2006. “The Pharmaceutical Person.” BioSocieties 1:.273-287.
Metzl, Jonathan and Rebecca Herzig. 2007. “Medicalisation in the 21st
Century: Introduction.” The Lancet 369(9562): 697-698.
Moynihan, Ray and Richard Smith. 2002. “Too Much Medicine? Almost
Certainly.” British Medical Journal 324(7342): 859-860.
Nichter, Mark. 1989. “Pharmaceuticals, the Commodification of Health, and
the Health Care-medicine Use Transition.” In Anthropology and
International Health: Asian Case Studies, edited by Mark Nichter and
Mini Nichter, 265-326. Amsterdam: Gordon and Breach Publishers.
Novas, Carlos. 2006. “The Political Economy of Hope: Patients’
Organizations, Science and Biovalue.” BioSocieties 1: 289-305.
Petryna, Adriana. 2006. “Globalizing Human Subjects Research.” In Global
Pharmaceuticals: Ethics, Markets, Practices, edited by Adriana Petryna,
Andrew Lakoff, and Arthur Kleinman, 33-60. Durham: Duke
University Press.
Rodeschini, Giulia. 2012. “Curare gli anziani: pratiche di cura in tensione tra
processi assistenziali e di medicalizzazione”. PhD Diss., Università
degli Studi di Trento, Scuola di Dottorato in Sociologia e Ricerca
Sociale.
Rose, Nicholas. 2007. The Politics of Life Itself. Princeton: Princeton University
Press.
Rossi, Paolo and Mara Tognetti Bordogna. 2013. “Mutual help without
borders? Plurality and heterogeneity of online mutual help practices
for people with long-term chronic conditions.” The European Journal of
Social Work 17(4): 523-538.
Sironi, Vittorio and Mara Tognetti Bordogna. 2009. “La politique du
médicament en Italie: histoire et perspectives.” Revue Sociologie Santé
30: 65-80.
Terraneo, Marco, Simone Sarti, and Mara Tognetti Bordogna. 2014. “Social
Inequalities and Pharmaceutical Cost Sharing in Italian Regions.”
International Journal of Health Services 44(4): 761–785.
Whitmarsh, Ian. 2008. “Biomedical ambivalence: Asthma Diagnosis, the
Pharmaceutical and Other Contradictions in Barbados.” American
Ethnologist 35(1): 40-63.
Williams, Simon, Jonathan Gabe, and Peter Davis. 2008. “The sociology of
pharmaceuticals: progress and prospects.” Sociology of Health & Illness
30(6): 813-824.
139
Williams, Simon J., Clive Seale, Sharon Boden, Pam Lowe, and Deborah
Lynn Steinberg. 2008. “Waking up to sleepiness: Modafinil, the
media and the pharmaceuticalisation of everyday/night life.”
Sociology of Health & Illness 30(6): 839-855.
Williams, Simon J. and Paul Martin. 2009. “Correspondence on cognitive
enhancement drugs for the healthy: risks and benefits may turn out
to be finely balanced.” Nature 457: 532.
Williams, Simon J., Paul Martin, and Jonathan Gabe. 2011a. “The
pharmaceuticalisation of society? A framework for analysis.”
Sociology of Health & Illness 33(5): 710-725.
Williams, Simon J., Paul Martin, and Jonathan Gabe. 2011b. “Evolving
sociological analyses of pharmaceuticalisation: a reply to Abraham
Sociology of Health & Illness 5: 729-730.
Williams, Simon J., Jonathan Gabe, and Paul Martin. 2012. “Medicalization
and pharmaceuticalization at the intersections: A commentary on
Bell and Figert.” Social Science & Medicine 75(12): 2129-2130.
Zola, Kenneth. 1972. “Medicine as an Institution of Social Control.”
Sociological Review 20(4): 487-504.
140

De La Medicalizacion A La Farmaceuticalizacion

Uploaded by

Copyright:

Available Formats

De La Medicalizacion A La Farmaceuticalizacion

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

De La Medicalizacion A La Farmaceuticalizacion

Uploaded by

Copyright:

Available Formats

From Medicalisation to Pharmaceuticalisation - A

Sociological Overview. New Scenarios for the Sociology

Mara Tognetti Bordogna ¹ ∗

The aim of this paper is to analyse the sociological

Medicaments are complementary to medicine: they support and justify one

Social Change Review ▪ Winter 2014 ▪ Vol. 12(2): 119-140

medication: with the development of multinational pharmaceutical

From medicalisation to pharmaceuticalisation

ability on the part of medicine to deal with pre-existing issues. Or do we

techno-scientific era of biomedicalisation (Clarke et al. 2003), while there is

industry, but in relation to increasing consumption of the product (Busfield

Pharmaceuticalisation of life and society

The process of pharmaceuticalisation is found in milieus that are

conditions into pharmaceutical questions of treatment or enhancement.

Disorder. As patents come to an end and brand drugs are replaced by

pharmaceuticalisation may not have increased in all fields of medicine: it is

1 Attention Deficit Hyperactivity Disorder (ADHD).

an increased pharmaceutical ability to meet and foresee health needs. It is

is a full-blown scientific and social concept. At least six social dimensions

the role of regulators vis-à-vis the patient demand to speed up approval of

pharmaceuticalising society: it may open up new channels of

pharmaceuticalisation together; in the second case, there is no involvement

revolution of biotechnology remains high, all the same, a fact that

We went on to show how in the Anglo-Saxon debate the notions of

Limits and future prospects

This paper does not claim to be exhaustive or generalizable: it is mainly a

aggregation and participation by individuals, and the different forms of

Transformations of Health and Illness in the U.S. Durham: Duke

Simon J. Williams, Jonathan Gabe and Peter Davis, 112-125. Oxford:

You might also like